Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.26 +3.00 (+0.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations August 29, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire 3 Strong Biotech Performers To Watch As Sector Nears Breakout August 17, 2023 As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. Via MarketBeat Topics ETFs Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine August 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports Second Quarter 2023 Financial Results August 01, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire 3 Biotech Stocks to Buy for Long-Term Gains July 13, 2023 The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. Via MarketBeat Topics ETFs Economy Exposures Interest Rates Vertex to Announce Second Quarter 2023 Financial Results on August 1 June 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Verve Therapeutics Gains 20.74% In June as Ark Funds Invest June 30, 2023 Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. Via MarketBeat Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies June 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions June 23, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Is the Biotech Industry (IBB) Poised For A Major Breakout? June 12, 2023 The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. Via MarketBeat Topics ETFs Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference June 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress June 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia June 08, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13 May 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire MarketBeat Week in Review – 5/15 - 5/19 May 20, 2023 Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities Via MarketBeat Topics Economy Electric Vehicles Exposures Economy Electric Vehicles Interest Rates Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings May 18, 2023 Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. Via MarketBeat Exposures Product Safety Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older May 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports First Quarter 2023 Financial Results May 01, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations April 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9 April 25, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Records 52-Week High Thursday Morning April 13, 2023 Via Investor Brand Network Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Wednesday Session April 12, 2023 Via Investor Brand Network Vertex to Announce First Quarter 2023 Financial Results on May 1 April 10, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia April 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire 3 Small Financial Software Makers Showing Strong Chart Action March 28, 2023 Financial software firms Intapp, Vertex, and GuidewIre are headed toward greater profitability and also boast strong chart action. Via MarketBeat Bullish News May Push Vertex Pharmaceuticals Above 52-Week High March 28, 2023 A recent announcement by Vertex Pharmaceuticals is confirming a technical signal that could allow the stock to make a new run at its 52-week high Via MarketBeat Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes March 27, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147) March 16, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes March 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7 February 21, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.